Table 5. Interaction between physical activity based on MET-minutes per week and PITX1 genetic variant in the risk of CRC stratified by anatomical sites and gender.
CC | AC/AA | P–interaction | |||||
---|---|---|---|---|---|---|---|
Low | Moderate | High | Low | Moderate | High | ||
Colorectal cancer | |||||||
All | |||||||
No. controls/cases | 222/106 | 213/111 | 235/77 | 219/126 | 229/157 | 208/108 | |
Crude OR (95% CI) | 1.00 (ref.) | 1.09 (0.79–1.51) | 0.69 (0.49–0.97) | 1.21 (0.88–1.66) | 1.44 (1.06–1.95) | 1.09 (0.78–1.51) | 0.263 |
Adjusted ORa (95% CI) | 1.00 (ref.) | 0.97 (0.67–1.40) | 0.56 (0.38–0.82) | 1.28 (0.90–1.83) | 1.29 (0.91–1.82) | 0.81 (0.56–1.17) | 0.649 |
Male | |||||||
No. controls/cases | 162/109 | 143/48 | 166/49 | 159/120 | 140/65 | 135/76 | |
Crude OR (95% CI) | 1.00 (ref.) | 0.50 (0.33–0.75) | 0.44 (0.29–0.66) | 1.12 (0.80–1.58) | 0.69 (0.47–1.01) | 0.84 (0.58–1.21) | 0.052 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 0.48 (0.30–0.76) | 0.34 (0.21–0.54) | 1.17 (0.79–1.73) | 0.63 (0.41–0.97) | 0.63 (0.41–0.96) | 0.157 |
Female | |||||||
No. controls/cases | 72/17 | 63/37 | 64/34 | 65/27 | 79/58 | 78/45 | |
Crude OR (95% CI) | 1.00 (ref.) | 2.49 (1.28–4.84) | 2.25 (1.15–4.41) | 1.76 (0.88–3.52) | 3.11 (1.66–5.83) | 2.44 (1.28–4.65) | 0.284 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 2.14 (1.03–4.44) | 1.79 (0.84–3.78) | 2.06 (0.96–4.41) | 3.08 (1.55–6.12) | 1.62 (0.79–3.32) | 0.091 |
Colon cancer | |||||||
All | |||||||
No. controls/cases | 222/49 | 213/53 | 235/44 | 219/64 | 229/84 | 208/54 | |
Crude OR (95% CI) | 1.00 (ref.) | 1.13 (0.73–1.74) | 0.85 (0.54–1.33) | 1.32 (0.87–2.01) | 1.66 (1.12–2.47) | 1.18 (0.77–1.81) | 0.854 |
Adjusted ORa (95% CI) | 1.00 (ref.) | 1.01 (0.64–1.60) | 0.69 (0.43–1.12) | 1.40 (0.90–2.18) | 1.50 (0.98–2.31) | 0.89 (0.56–1.41) | 0.903 |
Male | |||||||
No. controls/cases | 162/49 | 143/22 | 166/28 | 159/53 | 140/35 | 135/41 | |
Crude OR (95% CI) | 1.00 (ref.) | 0.51 (0.20–0.88) | 0.56 (0.33–0.93) | 1.10 (0.71–1.72) | 0.83 (0.51–1.35) | 1.00 (0.63–1.61) | 0.148 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 0.48 (0.27–0.88) | 0.43 (0.24–0.75) | 1.14 (0.71–1.85) | 0.75 (0.44–1.27) | 0.77 (0.46–1.30) | 0.165 |
Female | |||||||
No. controls/cases | 72/8 | 63/18 | 64/21 | 65/19 | 79/31 | 78/23 | |
Crude OR (95% CI) | 1.00 (ref.) | 2.57 (1.05–6.32) | 2.95 (1.22–7.13) | 2.63 (1.08–6.42) | 3.53 (1.52–8.18) | 2.65 (1.12–6.31) | 0.064 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 2.12 (0.81–5.53) | 2.22 (0.85–5.75) | 3.10 (1.19–8.06) | 3.39 (1.39–8.29) | 1.63 (0.64–4.14) | 0.028 |
Rectal cancer | |||||||
All | |||||||
No. controls/cases | 222/57 | 213/57 | 235/32 | 219/57 | 229/72 | 208/53 | |
Crude OR (95% CI) | 1.00 (ref.) | 1.04 (0.69–1.57) | 0.53 (0.33–0.85) | 1.01 (0.67–1.53) | 1.23 (0.83–1.82) | 0.99 (0.65–1.51) | 0.068 |
Adjusted ORa (95% CI) | 1.00 (ref.) | 0.91 (0.58–1.43) | 0.42 (0.25–0.70) | 1.10 (0.70–1.71) | 1.08 (0.70–1.66) | 0.72 (0.46–1.14) | 0.196 |
Male | |||||||
No. controls/cases | 162/60 | 143/26 | 166/20 | 159/65 | 140/30 | 135/35 | |
Crude OR (95% CI) | 1.00 (ref.) | 0.49 (0.29–0.82) | 0.33 (0.19–0.56) | 1.10 (0.73–1.67) | 0.58 (0.35–0.95) | 0.70 (0.44–1.13) | 0.081 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 0.47 (0.27–0.84) | 0.25 (0.14–0.46) | 1.16 (0.73–1.84) | 0.52 (0.30–0.90) | 0.50 (0.30–0.85) | 0.166 |
Female | |||||||
No. controls/cases | 72/9 | 63/19 | 64/12 | 65/6 | 79/25 | 78/21 | |
Crude OR (95% CI) | 1.00 (ref.) | 2.41 (1.02–5.71) | 1.50 (0.59–3.79) | 0.74 (0.25–2.19) | 2.53 (1.10–5.78) | 2.15 (0.93–5.01) | 0.472 |
Adjusted ORb (95% CI) | 1.00 (ref.) | 2.17 (0.87–5.40) | 1.26 (0.47–3.40) | 0.87 (0.28–2.69) | 2.57 (1.08–6.13) | 1.60 (0.65–3.96) | 0.648 |
aAdjusted for age, gender, education, alcohol, family history of CRC, total energy intake.
bAdjusted for age, education, alcohol, family history of CRC, total energy intake.
Physical activity-All: <1116 (low), 1116-<2925 (moderate), ≥2925 (High)
Physical activity-Male: <1386 (low), 1386-<3465 (moderate), ≥3465 (High)
Physical activity-Female: <660 (low), 660-<2079 (moderate), ≥2079 (High)